CA2817011C - Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity - Google Patents

Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity Download PDF

Info

Publication number
CA2817011C
CA2817011C CA2817011A CA2817011A CA2817011C CA 2817011 C CA2817011 C CA 2817011C CA 2817011 A CA2817011 A CA 2817011A CA 2817011 A CA2817011 A CA 2817011A CA 2817011 C CA2817011 C CA 2817011C
Authority
CA
Canada
Prior art keywords
leu
ala
ser
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2817011A
Other languages
English (en)
French (fr)
Other versions
CA2817011A1 (en
Inventor
Hung Do
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CA2817011A1 publication Critical patent/CA2817011A1/en
Application granted granted Critical
Publication of CA2817011C publication Critical patent/CA2817011C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2817011A 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity Active CA2817011C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US61/411,331 2010-11-08
US41218010P 2010-11-10 2010-11-10
US61/412,180 2010-11-10
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Publications (2)

Publication Number Publication Date
CA2817011A1 CA2817011A1 (en) 2012-05-18
CA2817011C true CA2817011C (en) 2019-04-02

Family

ID=46051505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817011A Active CA2817011C (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Country Status (19)

Country Link
US (4) US8962564B2 (enExample)
EP (2) EP2638152B1 (enExample)
JP (2) JP6073796B2 (enExample)
KR (1) KR101901467B1 (enExample)
CN (2) CN103314105B (enExample)
BR (1) BR112013011152A2 (enExample)
CA (1) CA2817011C (enExample)
CY (1) CY1118843T1 (enExample)
DK (1) DK2638152T3 (enExample)
ES (2) ES2743825T3 (enExample)
HR (1) HRP20161560T1 (enExample)
HU (1) HUE030932T2 (enExample)
LT (1) LT2638152T (enExample)
PL (1) PL2638152T3 (enExample)
PT (1) PT2638152T (enExample)
RS (1) RS55405B1 (enExample)
SI (1) SI2638152T1 (enExample)
SM (1) SMT201600431B (enExample)
WO (1) WO2012064709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125892A1 (en) * 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
FI3850089T3 (fi) 2019-02-04 2024-02-14 Freeline Therapeutics Ltd Polynukleotidejä
JP2022547297A (ja) 2019-09-09 2022-11-11 エフ.ホフマン-ラ ロシュ アーゲー グルコセレブロシダーゼ変異体
US20230132790A1 (en) * 2020-03-29 2023-05-04 Yeda Research And Development Co. Ltd. Variants of beta-glucocerebrosidase for use in treating gaucher disease
CA3189801A1 (en) * 2020-07-29 2022-02-03 Freeline Therapeutics Limited Polypeptide
WO2023145814A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 向上した酵素活性または向上した安定性を有する組換えグルコセレブロシダーゼタンパク質
JPWO2023145813A1 (enExample) * 2022-01-31 2023-08-03
US20250145978A1 (en) * 2022-01-31 2025-05-08 Nippon Shokubai Co., Ltd. Glycosylated protein having glucocerebrosidase activity
EP4508206A1 (en) 2022-04-12 2025-02-19 F. Hoffmann-La Roche AG Fusion proteins targeted to the central nervous system
CN118715316B (zh) * 2022-10-08 2025-09-19 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
WO2025122912A1 (en) * 2023-12-08 2025-06-12 Denali Therapeutics Inc. Modified glucocerebrosidase polypeptides and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
DE68926569T2 (de) 1988-12-23 1996-09-26 Genzyme Corp Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren
EP0979311A1 (en) 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
EP1027069B1 (en) * 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
IL141403A0 (en) * 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
IL150314A0 (en) * 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
AU2001253181A1 (en) * 2000-04-06 2001-10-23 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
WO2002002597A2 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
EP1613264A4 (en) * 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
KR20100017879A (ko) * 2007-05-22 2010-02-16 아미쿠스 세라퓨틱스, 인코포레이티드 이소파고민과 이의 유도체를 제조하는 새로운 방법
US20090148887A1 (en) 2007-11-02 2009-06-11 The Scripps Research Institute Genetically encoded boronate amino acid
BRPI0819092A2 (pt) 2007-11-02 2014-10-14 Scripps Research Inst Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.

Also Published As

Publication number Publication date
HUE030932T2 (en) 2017-06-28
SMT201600431B (it) 2017-01-10
DK2638152T3 (en) 2016-12-12
CN103314105A (zh) 2013-09-18
EP2638152A4 (en) 2014-04-09
JP2014500722A (ja) 2014-01-16
EP3144386A1 (en) 2017-03-22
WO2012064709A2 (en) 2012-05-18
PL2638152T3 (pl) 2017-02-28
RS55405B1 (sr) 2017-04-28
KR101901467B1 (ko) 2018-11-02
US8962564B2 (en) 2015-02-24
WO2012064709A3 (en) 2012-08-02
EP3144386B1 (en) 2019-05-29
CN105296447A (zh) 2016-02-03
PT2638152T (pt) 2016-10-25
CN103314105B (zh) 2015-11-25
JP6073796B2 (ja) 2017-02-01
JP2017099390A (ja) 2017-06-08
US20170157220A1 (en) 2017-06-08
LT2638152T (lt) 2016-12-12
KR20140009238A (ko) 2014-01-22
BR112013011152A2 (pt) 2016-11-29
SI2638152T1 (sl) 2016-12-30
ES2604490T3 (es) 2017-03-07
US20130344054A1 (en) 2013-12-26
ES2743825T3 (es) 2020-02-20
JP6457559B2 (ja) 2019-01-23
US9566316B2 (en) 2017-02-14
HRP20161560T1 (hr) 2016-12-30
EP2638152B1 (en) 2016-08-31
US9821038B2 (en) 2017-11-21
EP2638152A2 (en) 2013-09-18
US20160184408A1 (en) 2016-06-30
US9254313B2 (en) 2016-02-09
CY1118843T1 (el) 2018-01-10
CA2817011A1 (en) 2012-05-18
US20150216950A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
CA2817011C (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
US7122354B2 (en) Nucleic acid encoding a chimeric polypeptide
CA2265464C (en) Therapy for .alpha.-galactosidase a deficiency
WO2019038197A1 (en) IMPROVED TRANSPOSASE POLYPEPTIDE AND USES THEREOF
HK1189624B (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
HK1235826A1 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
AU762400B2 (en) Therapy for alpha-galactosidase a deficiency
HK1162580B (en) Purification process of alpha-galactosidase a
HK1157398A (en) Therapy for alpha-galactosidase a deficiency
HK1074058B (en) Production of human alpha-galactosidase a

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161102